Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

A regiszterben nem jelölt feltételek

• The study cohort is limited to employees and adult dependents aged 18-64 who receive their health insurance coverage from self-insured Indiana employers that agree to participate in the study.
• To be included in the study, the individuals must:
• Be an Indiana resident;
• Have health insurance benefits provided by participating employers (includes employees and dependents);
• Be between the ages of 18 and 64;
• Meet the eligibility criteria for an obesity medication prescription:
  • BMI of ≥ 30 (obesity) or
  • BMI of ≥ 25 (overweight) and at least one body weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). If the prescribing eligibility criteria are updated in the future, we will update accordingly.
• Individuals must have at least 6 months of enrollment prior to study inclusion (i.e., prior to the index date), though we may use additional pre-treatment data if available.
  • An individual who meets any of the following criteria will be excluded from participation in the cohort:
• Has a condition associated with weight loss: a diagnosis of cancer (except for non-melanoma skin cancer), pancreatitis, eating disorders (e.g., anorexia nervosa and avoidant restrictive food intake disorder), HIV, unintentional weight loss, or cirrhosis at baseline;
• Has a condition for which obesity medications are contraindicated (for example, medullary thyroid carcinoma, multiple endocrine neoplasia, etc.).
• Receipt of diabetes-indicated incretin-based medications. If an individual has a claim for a related incretin-based therapy diabetes medication (e.g., Mounjaro, Ozempic, Rybelsus, Victoza) without an obesity-medication claim during the study period, the individual will be excluded from analysis.
• Prior bariatric surgery.
• Evidence of prior use of incretin-based obesity medications for weight loss.